
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Under Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
May 5, 2022

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-15317
(Commission
File Number)

98-0152841
(I.R.S. Employer
Identification No.)

9001 Spectrum Center Blvd.
San Diego, California 92123
(Address of Principal Executive Offices)

(858) 836-5000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.004 par value	RMD	NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 5, 2022, we announced that Jim Hollingshead resigned as our president – sleep and respiratory care business, effective as of May 5, 2022, to pursue an opportunity with a new employer. In connection with his resignation, Robert (“Rob”) Douglas, our president and chief operating officer, has been appointed to serve as our interim president – sleep and respiratory care business. We intend to commence a search for a permanent president – sleep and respiratory care business. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

Mr. Douglas was appointed ResMed Inc.’s president in March 2013 and chief operating officer in September 2011; together with ResMed’s chief executive officer, Michael (“Mick”) Farrell, he holds full operational responsibility for ResMed and its subsidiaries.

There are no family relationships between Mr. Douglas and any director or executive officer of ResMed that are required to be disclosed under Item 401(d) of Regulation S-K, and there are no transactions between ResMed and Mr. Douglas that would require disclosure under Item 404(a) of Regulation S-K. The information concerning Mr. Douglas required under Item 401 of Regulation S-K is contained in ResMed’s proxy statement dated October 6, 2021 and is incorporated here by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 [Press release issued by ResMed Inc. on May 5, 2022.](#)

104 Cover Page Interactive Data File (embedded within the Inline XBRL, document)

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: May 11, 2022

RESMED INC.
(registrant)

By: /s/ David Pendarvis

Name: David Pendarvis

Its: Chief administrative officer, global general
counsel and secretary



For media

Jayne Rubenstein
+1 858-836-6798
news@resmed.com

For investors

Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

ResMed Announces Leadership Change

SAN DIEGO, May 5, 2022 – ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new position and is leaving the company, effective immediately. Rob Douglas, President and Chief Operating Officer, has been appointed interim President, Sleep and Respiratory Care.

“I’d like to thank Jim for his 12 years of service and valuable contributions to ResMed,” said Mick Farrell, ResMed CEO. “Jim has played an important role in our business, first as head of our strategy and business development team, then as president of our Americas region, and most recently as president of our Sleep and Respiratory Care business. Jim formed part of the global business team that created the strategy to embed communications in our devices, supporting our transformation into a world-leading digital health company. Together with our CEO operations team, Jim has helped curate a team of strong leaders, leaving ResMed well positioned for ongoing growth, as we accelerate our business into 2025, and beyond. I wish Jim well in his new role as a ResMed alum, and I thank Rob for stepping in on an interim basis, as together we build upon our strong leadership bench-strength here at ResMed.”

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit [ResMed.com](https://www.resmed.com) and follow [@ResMed](https://twitter.com/ResMed).

###